Century Therapeutics employs induced pluripotent stem cells combined with their Allo-Evasion™ gene editing platform to develop off-the-shelf allogeneic therapies targeting autoimmune diseases and cancer. The company has notably reduced its operating losses by over 80% year-over-year while advancing its lead candidate CNTY-813 for type 1 diabetes into IND-enabling studies. Despite robust liquidity and integrated manufacturing capabilities, Century faces clinical, manufacturing, and regulatory execution risks typical of emerging cell therapy developers. Upcoming clinical milestones and manufacturing scale validation represent critical inflection points for the firm’s transition toward commercialization readiness.